37 research outputs found
News from the Muon (g-2) Experiment at BNL
The magnetic moment anomaly a_mu = (g_mu - 2) / 2 of the positive muon has
been measured at the Brookhaven Alternating Gradient Synchrotron with an
uncertainty of 0.7 ppm. The new result, based on data taken in 2000, agrees
well with previous measurements. Standard Model evaluations currently differ
from the experimental result by 1.6 to 3.0 standard deviations.Comment: Talk presented at RADCOR - Loops and Legs 2002, Kloster Banz,
Germany, September 8-13 2002, to be published in Nuclear Physics B (Proc.
Suppl.); 5 pages, 3 figure
Measurement of e+e- -> pi+pi- cross section with CMD-2 around rho-meson
The cross section of the process e+e- -> pi+pi- has been measured using about
114000 events collected by the CMD-2 detector at the VEPP-2M e+e- collider in
the center-of-mass energy range from 0.61 to 0.96 GeV. Results of the pion form
factor determination with a 0.6% systematic uncertainty are presented.
Implications for the hadronic contribution to the muon anomalous magnetic
moment are discussed.Comment: 17 pages, 4 figures, submitted to PL
Measurement of the Positive Muon Anomalous Magnetic Moment to 0.46 ppm
We present the first results of the Fermilab Muon g-2 Experiment for the
positive muon magnetic anomaly . The anomaly is
determined from the precision measurements of two angular frequencies.
Intensity variation of high-energy positrons from muon decays directly encodes
the difference frequency between the spin-precession and cyclotron
frequencies for polarized muons in a magnetic storage ring. The storage ring
magnetic field is measured using nuclear magnetic resonance probes calibrated
in terms of the equivalent proton spin precession frequency
in a spherical water sample at 34.7C. The
ratio , together with known fundamental
constants, determines
(0.46\,ppm). The result is 3.3 standard deviations greater than the standard
model prediction and is in excellent agreement with the previous Brookhaven
National Laboratory (BNL) E821 measurement. After combination with previous
measurements of both and , the new experimental average of
(0.35\,ppm) increases the
tension between experiment and theory to 4.2 standard deviationsComment: 10 pages; 4 figure
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context
Long noncoding RNAs (lncRNAs) are commonly dysregulated in tumors, but only a handful are known to play pathophysiological roles in cancer. We inferred lncRNAs that dysregulate cancer pathways, oncogenes, and tumor suppressors (cancer genes) by modeling their effects on the activity of transcription factors, RNA-binding proteins, and microRNAs in 5,185 TCGA tumors and 1,019 ENCODE assays. Our predictions included hundreds of candidate onco- and tumor-suppressor lncRNAs (cancer lncRNAs) whose somatic alterations account for the dysregulation of dozens of cancer genes and pathways in each of 14 tumor contexts. To demonstrate proof of concept, we showed that perturbations targeting OIP5-AS1 (an inferred tumor suppressor) and TUG1 and WT1-AS (inferred onco-lncRNAs) dysregulated cancer genes and altered proliferation of breast and gynecologic cancer cells. Our analysis indicates that, although most lncRNAs are dysregulated in a tumor-specific manner, some, including OIP5-AS1, TUG1, NEAT1, MEG3, and TSIX, synergistically dysregulate cancer pathways in multiple tumor contexts. Chiu et al. present a pan-cancer analysis of lncRNA regulatory interactions. They suggest that the dysregulation of hundreds of lncRNAs target and alter the expression of cancer genes and pathways in each tumor context. This implies that hundreds of lncRNAs can alter tumor phenotypes in each tumor context